[Back to Issue 12 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]
[View Full Article] [Download Reprint (PDF)]

Is an Expression System for Producing Therapeutic Antibodies with Immunosuppressive Properties Found at Last? Comment to Letter by Dr. Quagliaroli

N. I. Olovnikova

Hematology Research Center, Ministry of Health, Novyi Zykovskii Proezd 4A, 125167 Moscow, Russia; fax: (495) 612-3521; E-mail: nolov@blood.ru

Received September 9, 2013
The prophylaxis of the hemolytic disease of the newborn – a mandatory procedure in obstetrics – requires significant amounts of plasma-derived polyclonal anti-D immunoglobulin. Despite numerous attempts, the proper technology for mass production of effective monoclonal anti-D is still not available. LFB Biotechnologies is currently performing clinical trials with recombinant anti-D antibody that has low fucose content and is expressed in the cells of rat myeloma YB2/0. It was shown that this drug is well tolerated, accelerates fast clearance of D+ red blood cells, and can inhibit anti-D immune response in Rhesus-negative volunteers.
KEY WORDS: anti-D monoclonal antibodies, Roledumab, glycosylation, alloimmunization, clinical trials

DOI: 10.1134/S0006297913120092